Literature DB >> 33022533

Modeling of osteosarcoma with induced pluripotent stem cells.

Lon Kai Pang1, Mezthly Pena1, Ruiying Zhao2, Dung-Fang Lee3.   

Abstract

Osteosarcoma is the most common type of bone cancer. Osteosarcoma is commonly associated with TP53 inactivation (around 95% of cases) and RB1 inactivation (around 28% of cases). With the discovery of reprogramming factors to induce pluripotency even in terminally differentiated cells, induced pluripotent stem cells (iPSCs) have emerged as a promising disease model. iPSC-based disease modeling uniquely recapitulates disease phenotypes and can support discoveries into disease etiology and is used extensively today to study a variety of diseases, including cancers. This paper focuses on iPSC-based modeling of Li-Fraumeni syndrome (LFS), an autosomal dominant disorder commonly associated with TP53 mutation and high osteosarcoma incidence. As iPSCs are increasingly utilized as a platform for cancer modeling, the experimental approaches that we discuss here may serve as a guide for future studies.
Copyright © 2020 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cancer etiology; Dinduced pluripotent stem cells; H19; Li-Fraumeni syndrome; Osteosarcoma; SFRP2; p53 mutation

Mesh:

Year:  2020        PMID: 33022533     DOI: 10.1016/j.scr.2020.102006

Source DB:  PubMed          Journal:  Stem Cell Res        ISSN: 1873-5061            Impact factor:   2.020


  2 in total

Review 1.  Melanoma in patients with Li-Fraumeni syndrome (Review).

Authors:  Florica Sandru; Mihai Cristian Dumitrascu; Aida Petca; Mara Carsote; Razvan-Cosmin Petca; Adina Ghemigian
Journal:  Exp Ther Med       Date:  2021-11-24       Impact factor: 2.447

2.  Patient-derived iPSCs link elevated mitochondrial respiratory complex I function to osteosarcoma in Rothmund-Thomson syndrome.

Authors:  Brittany E Jewell; An Xu; Dandan Zhu; Mo-Fan Huang; Linchao Lu; Mo Liu; Erica L Underwood; Jun Hyoung Park; Huihui Fan; Julian A Gingold; Ruoji Zhou; Jian Tu; Zijun Huo; Ying Liu; Weidong Jin; Yi-Hung Chen; Yitian Xu; Shu-Hsia Chen; Nino Rainusso; Nathaniel K Berg; Danielle A Bazer; Christopher Vellano; Philip Jones; Holger K Eltzschig; Zhongming Zhao; Benny Abraham Kaipparettu; Ruiying Zhao; Lisa L Wang; Dung-Fang Lee
Journal:  PLoS Genet       Date:  2021-12-29       Impact factor: 6.020

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.